Making the impossible, possible
At Arvinas, we’re leading the creation of an entirely new way to treat disease through therapies that target and degrade disease-related proteins. We are a clinical-stage biopharmaceutical company focused on developing new therapeutics for cancers and other difficult-to-treat diseases. Our proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras, work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
We have built upon groundbreaking research of our founder Dr. Craig Crews of Yale University to develop a broad technology platform focused on high-value targets, with the potential to deliver more potent therapies and to address the >80% of proteins that evade inhibition and have been “undruggable” by traditional approaches.
Our leading programs are focused on high-value targets in cancer, including the androgen and estrogen receptors associated with prostate and breast cancers, respectively. Our hope is to unlock the full potential of PROTAC protein degradation by developing our own robust pipeline and by partnering with the world’s leading drug development companies.